Associated Papers
Breast cancer risks associated with missense variants in breast cancer susceptibility genes.
Dorling L et al.
Genome Medicine, 2022
35585550 (PubMed )
Supplement: 13073_2022_1052_MOESM2_ESM.xlsx › Table_S16
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
36561320 (PubMed )
Supplement: Table2.xlsx › BRCA2
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome.
Fanale D et al.
Frontiers in Oncology, 2021
Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort.
Li H et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2020
31853058 (PubMed )
Supplement: 41436_2019_729_MOESM3_ESM.xls › Sheet1
A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer.
Li D et al.
Scientific Reports, 2014
25323003 (PubMed )
Supplement: srep06666-s1.pdf
Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer.
Fang YY et al.
Bmc Cancer, 2014
24629067 (PubMed )
Supplement: 1471-2407-14-188-S1.pdf
BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
Li D et al.
Cell Cycle (georgetown, Tex.), 2014
25486197 (PubMed )
Supplement: supplement_1.pdf
Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer.
Li D et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2013
24321281 (PubMed )
Supplement: 1756-9966-32-102-S1.pdf
Select a paper to view details